Physician profile
Steven Lai
NPI 1992061345
$814.74
in general payments reported to CMS, 2019-2025
15 companies · $399 in 2025
The $399 reported for 2025 was more than what 91% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $13.68 · 2023: $129 · 2024: $152 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $171.71 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Shionogi INC | $121.40 | 2021 | |
| Kite Pharma, INC. | $108.72 | 2025 | Yescarta |
| Astellas Pharma US INC | $52.61 | 2023-2024 | Xospata |
| Merck Sharp & Dohme LLC | $51.72 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $50.18 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $48.86 | 2024-2025 | Tecentriq |
| Mirati Therapeutics, INC. | $42.27 | 2023-2024 | Krazati |
| Lilly USA, LLC | $33.88 | 2025 | Verzenio, Jaypirca |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Eisai INC. | $25.42 | 2025 | |
| Daiichi Sankyo INC. | $24.40 | 2024 | Enhertu |
| Pfizer INC. | $21.41 | 2024 | |
| Kyowa Kirin, INC. | $18.31 | 2025 | |
| Gilead Sciences, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.